Singapore Clinical Trial: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study... Read More

Singapore Clinical Trial: Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the o... Read More

Clinical Trial: Goal Directed Fluid Therapy in Craniotomy Operations Guided By Pulse Pressure Variability (PPV) Versus Central Venous Pressure (CVP)

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787455) titled 'Goal Directed Fluid Therapy in Craniotomy Operations Guided By Pulse Pressure Variability (... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More

Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More

Singapore Clinical Trial: A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hypertensive patients.

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hy... Read More

Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascim... Read More

Clinical Trial: SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787338) titled 'SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Posit... Read More

Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, Aug. 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy ... Read More

• ««
• «
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• »
• »»